COMPARE: Losartan shows promising results in patients with Marfan syndrome

Patients with Marfan syndrome (connective tissue disorder) are more susceptible to aortic dilation and consequently dissection and sudden death. Current treatment recommends prophylactic surgery when it reaches a measurement between 46-50 mm (IC) or when it is > 50 mm (IIa C) associated with beta-blocker treatment. The role of losartan added to this therapy is not well established.

113 patients were  randomized with a diagnosis of Marfan, aorta

The primary end point was the dilation of the aortic arch at any level at 3 years. In the follow-up MRI performed, patients treated with losartan had lower aortic arch dilation than patients in the placebo group. During follow-up, 9 patients in both groups required surgery, 2 patients developed dissection in the control group. 

Conclusion:

In patients with Marfan syndrome using losartan showed a significant reduction of aortic dilatation.

Read article

Maarten%20Groenink_presentacion
Maarten Groenink
2013-09-02

Original title: COMPARE: Effect of losartan on aortic dilatation rate in adults with Marfan Syndrome

More articles by this author

PURE: Cardiovascular disease contrast between developed and undeveloped countries.

80% of the global burden of cardiovascular disease is located in countries with low or middle incomes. The aim of this study was to...

SAVOR-TIMI 53: Saxagliptin showed no cardiovascular benefit

The cardiovascular safety and efficacy of some hypoglycemic including saxagliptin (Onglyza), an inhibitor of dipeptidyl peptidase 4 (DPP-4), is not well established. 16492 patients were...

ASSURE: Inducing Apo A-1 agent failed to reduce atherosclerotic plaque

Induction apoA-1  synthesis is a new therapeutic approach for the functional HDL particles generation. The RVX-208 induces apoA-1  synthesis with favorable effect on HDL...

EXAMINE: The alogliptin is safe for treating type 2 diabetes in patients with a recent history of acute coronary syndrome.

Type 2 diabetes is associated both microvascular and macrovascular disease. Adequate glycemic control can reduce the risk of many microvascular complications but have not...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...